IQVIA (NYSE:IQV) Downgraded to Hold at StockNews.com

StockNews.com downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a report issued on Tuesday.

IQV has been the topic of several other research reports. Argus raised IQVIA to a strong-buy rating in a research report on Wednesday, July 31st. Morgan Stanley upped their price objective on IQVIA from $270.00 to $280.00 and gave the company an overweight rating in a research report on Tuesday, July 23rd. Truist Financial increased their price target on IQVIA from $292.00 to $300.00 and gave the stock a buy rating in a research report on Tuesday, July 23rd. Barclays increased their price target on IQVIA from $255.00 to $275.00 and gave the stock an overweight rating in a research report on Tuesday, July 23rd. Finally, Robert W. Baird increased their price target on IQVIA from $235.00 to $251.00 and gave the stock a neutral rating in a research report on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $265.67.

IQVIA Stock Up 0.3 %

NYSE IQV opened at $248.60 on Tuesday. The stock’s 50 day moving average is $229.20 and its 200 day moving average is $233.75. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market cap of $45.29 billion, a PE ratio of 33.96, a P/E/G ratio of 2.26 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the firm earned $2.22 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. Research analysts predict that IQVIA will post 10.24 EPS for the current fiscal year.

Institutional Trading of IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of IQV. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter valued at approximately $27,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA in the second quarter valued at approximately $29,000. Rise Advisors LLC acquired a new stake in IQVIA in the first quarter valued at approximately $31,000. Finally, Riverview Trust Co acquired a new stake in IQVIA in the first quarter valued at approximately $32,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.